Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 10/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | WNT1 | P04628 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25295958 | 1.00 | IRAK4 (0.38) | IRAK4MCHR1KCNH2CYP3A4KRAS | |
| SCHEMBL25295957 | 1.00 | IRAK4 (0.38) | IRAK4MCHR1KCNH2CYP3A4KRAS | |
| SCHEMBL145462 | 0.84 | HDAC3 (0.44) | IRAK4MCHR1MCHR2HDAC3HDAC2 | |
| SCHEMBL17678319 | 0.79 | EGFR (0.41) | IRAK4MCHR1MCHR2HDAC3HDAC2 | |
| SCHEMBL17678307 | 0.79 | IRAK4 (0.40) | IRAK4MCHR1KCNH2CYP3A4MCHR2 | |
| SCHEMBL15328505 | 0.78 | IRAK4 (0.43) | IRAK4HDAC2ROCK1HDAC1 | |
| SCHEMBL15328953 | 0.78 | IRAK4 (0.45) | IRAK4ROCK1GSK3B | |
| SCHEMBL23533661 | 0.77 | HTR7 (0.42) | MCHR1KCNH2CYP3A4KRASMCHR2 | |
| SCHEMBL23533660 | 0.77 | HTR7 (0.42) | MCHR1KCNH2CYP3A4KRASMCHR2 | |
| SCHEMBL17678143 | 0.76 | IRAK4 (0.49) | IRAK4MCHR1MCHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | NOVARTIS AG (CH) | 2023-07-18 | — | — | US | disclosed |
| US-20220363670-A1 | Pyrazolyl derivatives useful as anti-cancer agents | NOVARTIS AG (CH) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | PAK5, CYP51A1, SF3B5 | IRAK4 2306/4885MCHR1 4865/4885KCNH2 4437/4885 |
| US-20220363670-A1 | Pyrazolyl derivatives useful as anti-cancer agents | PAK5, CYP51A1, SF3B5 | IRAK4 2306/4885MCHR1 4865/4885KCNH2 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.